Top Markets
#1 Bitway Bitway +52.95%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +40.72%
#3 Pons Pons +35.43%
#4 Starpower Starpower +34.87%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.49%
#6 SkyAI SkyAI +19.55%
#7 aelf aelf +19.41%
#8 OpenEden OpenEden +19.38%
#9 Ocean Protocol Ocean Protocol +17.12%
#10 PondCoin PondCoin +16.42%
Coin of the day
Bitway Bitway
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Classement en actions #29318
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Prix de l'action
$0.62008105
Dernière synchronisation: 2026-08-18
Capitalisation boursière
$21.81M
Changement (1 jour)
0.26%
Changement (1 an)
-31.95%
Pays
TW
Échange SynCore Biotechnology Co.,Ltd (4192)

Catégorie

Healthcare
Revenus pour SynCore Biotechnology Co.,Ltd (4192)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de SynCore Biotechnology Co.,Ltd, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour SynCore Biotechnology Co.,Ltd de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH